ProQR Therapeutics N.V. (NASDAQ: PRQR) has recently received a number of price target changes and ratings updates:

  • 10/6/2017 – ProQR Therapeutics N.V. was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
  • 10/3/2017 – ProQR Therapeutics N.V. was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $5.50 price target on the stock. According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
  • 9/30/2017 – ProQR Therapeutics N.V. was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
  • 9/26/2017 – ProQR Therapeutics N.V. had its price target raised by analysts at JMP Securities from $14.00 to $20.00. They now have an “outperform” rating on the stock.
  • 9/26/2017 – ProQR Therapeutics N.V. had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
  • 9/26/2017 – ProQR Therapeutics N.V. had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $12.00 price target on the stock, up previously from $10.00.
  • 9/26/2017 – ProQR Therapeutics N.V. was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 9/17/2017 – ProQR Therapeutics N.V. had its “neutral” rating reaffirmed by analysts at Chardan Capital.
  • 9/15/2017 – ProQR Therapeutics N.V. was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 9/13/2017 – ProQR Therapeutics N.V. was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $6.00 price target on the stock. According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
  • 9/12/2017 – ProQR Therapeutics N.V. was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
  • 9/1/2017 – ProQR Therapeutics N.V. was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 8/30/2017 – ProQR Therapeutics N.V. was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $5.25 price target on the stock. According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
  • 8/29/2017 – ProQR Therapeutics N.V. was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
  • 8/22/2017 – ProQR Therapeutics N.V. was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $5.25 price target on the stock. According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “

Shares of ProQR Therapeutics N.V. (NASDAQ PRQR) remained flat at $4.55 on Tuesday. The company’s stock had a trading volume of 49,557 shares. The company’s 50-day moving average is $5.18 and its 200 day moving average is $5.05. The firm’s market cap is $109.68 million. ProQR Therapeutics N.V. has a 12 month low of $3.65 and a 12 month high of $8.70.

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Receive News & Ratings for ProQR Therapeutics NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics NV and related companies with MarketBeat.com's FREE daily email newsletter.